Structure Therapeutics Inc.

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. It is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis.